Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Dawson S, Duffy S, Blows F, et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer. 2009;101(8):1338.
   PubMed Web of Science ®Google Scholar
• Yan B, Yang L-M, Hao L-P, et al. Determinants of quality of life for breast cancer patients in Shanghai, China. Plos One. 2016;11(4):e0153714.
   PubMed Web of Science ®Google Scholar
• Barratt A. Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality. BMJ. 2015;350:h867.
   PubMed Web of Science ®Google Scholar
• de Haes JC, de Koning HJ, van Oortmarssen GJ, et al. The impact of a breast cancer screening programme on quality-adjusted life-years. Int J Cancer. 1991;49(4):538–544.
   PubMed Web of Science ®Google Scholar
• Elder K, Nickson C, Pattanasri M, et al. Treatment intensity differences after early-stage breast cancer (ESBC) diagnosis depending on participation in a screening program. Ann Surg Oncol. 2018;25(9):2563–2572.
   Web of Science ®Google Scholar
• Kalager M, Tamimi RM, Bretthauer M, et al. Prognosis in women with interval breast cancer: population based observational cohort study. BMJ. 2012;345:e7536.
   PubMed Web of Science ®Google Scholar
• Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. JNCI. 2000;92(9):743–749.
   PubMedGoogle Scholar
• Cortesi L, Chiuri VE, Ruscelli S, et al. Prognosis of screen-detected breast cancers: results of a population based study. BMC Cancer. 2006;6(1):17.
   PubMed Web of Science ®Google Scholar
• Kemp-Casey A, Roughead EE, Saunders C, et al. Breast cancer recurrence following active treatment: determining its incidence in the NSW population. Public Health Res Pract. 2016;26(1):e2611607–e2611607.
   PubMed Web of Science ®Google Scholar
• Carter SM, Rogers W, Heath I, et al. The challenge of overdiagnosis begins with its definition. BMJ. 2015;350:h869.
   PubMed Web of Science ®Google Scholar
• van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, et al. Simulating the impact of risk-based screening and treatment on breast cancer outcomes with MISCAN-Fadia. Med Decis Mak. 2018;38(1_suppl):54S–65S.
   PubMed Web of Science ®Google Scholar
• Raftery J, Chorozoglou M. Possible net harms of breast cancer screening: updated modelling of Forrest report. BMJ. 2011;343:d7627.
   PubMed Web of Science ®Google Scholar
• Morton R, Sayma M, Sura MS. Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained? Breast Cancer: Target Therapy. 2017;9:217.
   PubMed Web of Science ®Google Scholar
• Stout NK, Rosenberg MA, Trentham-Dietz A, et al. Retrospective cost-effectiveness analysis of screening mammography. JNCI. 2006;98(11):774–782.
   PubMed Web of Science ®Google Scholar
• Arrospide A, Rue M, van Ravesteyn NT, et al. Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis. BMC Cancer. 2016;16(1):344.
   PubMed Web of Science ®Google Scholar
• Gocgun Y, Banjevic D, Taghipour S, et al. Cost-effectiveness of breast cancer screening policies using simulation. Breast. 2015;24(4):440–448.
   PubMed Web of Science ®Google Scholar
• Arveux P, Wait S, Schaffer P. Building a model to determine the cost‐effectiveness of breast cancer screening in France. Eur J Cancer Care (Engl). 2003;12(2):143–153.
   PubMed Web of Science ®Google Scholar
• BreastScreen Australia. BreastScreen Australia Evaluation. Evaluation final report. Canberra: Australian Government Department of Health and Ageing; 2009 Jun. Report No.: Screening Monograph No.1. 2009.
   Google Scholar
• Rojnik K, Naveršnik K, Mateović-Rojnik T, et al. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. Value Health. 2008;11(2):139–148.
   PubMed Web of Science ®Google Scholar
• Wolters R, Regierer AC, Schwentner L, et al. A comparison of international breast cancer guidelines – do the national guidelines differ in treatment recommendations? Eur J Cancer. 2012;48(1):1–11.
   PubMed Web of Science ®Google Scholar
• Frasier LL, Holden S, Holden T, et al. Temporal trends in postmastectomy radiation therapy and breast reconstruction associated with changes in national comprehensive cancer network guidelines. JAMA Oncol. 2016;2(1):95–101.
   PubMed Web of Science ®Google Scholar
• Pattanasri M, Elder K, Nickson C, et al. Uptake of adjuvant breast cancer treatments recommended by multi‐disciplinary meetings. ANZ J Surg. 2018;88(7–8):745–750.
   Web of Science ®Google Scholar
• Li L, Severens JL, Mandrik O. Disutility associated with cancer screening programs: a systematic review. PloS One. 2019;14(7):e0220148.
   PubMed Web of Science ®Google Scholar
• Skedgel C, Rayson D, Dewar R, et al. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat. 2007;101(3):325–333.
   PubMed Web of Science ®Google Scholar
• Hackshaw A, Roughton M, Forsyth S, et al. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011;29(13):1657–1663.
   PubMed Web of Science ®Google Scholar
• Milata JL, Otte JL, Carpenter JS. Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. Cancer Nurs. 2018;41(1):E9–E18.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21.
   PubMed Web of Science ®Google Scholar
• AIHW. Cancer data in Australia. Australian Institute of Health and Welfare. 2020. Cat. no: CAN 122
   Google Scholar
• Bromley HL, Mann GB, Petrie D, et al. Valuing preferences for treating screen detected ductal carcinoma in situ. Eur J Cancer. 2019;123:130–137.
   PubMed Web of Science ®Google Scholar
• Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost-effectiveness analysis in healthcare. Vol. 3. Oxford University Press, Oxford; 2011.
   Google Scholar
• Bromley HL, Petrie D, Mann GB, et al. Valuing the health states associated with breast cancer screening programmes: a systematic review of economic measures. Soc Sci Med. 2019;228:142–154.
   PubMed Web of Science ®Google Scholar
• de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer. 1991;49(4):531–537.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jonsson B, et al. Health related quality of life in different states of breast cancer. Qual Life Res. 2007;16(6):1073–1081.
   PubMed Web of Science ®Google Scholar
• Fallowfield L. Acceptance of adjuvant therapy and quality of life issues. Breast. 2005;14(6):612–616.
   PubMed Web of Science ®Google Scholar
• Bender CM, Gentry AL, Brufsky AM, et al. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum. 2014;41(3):274–285.
   PubMed Web of Science ®Google Scholar
• Paraskevi T. Quality of life outcomes in patients with breast cancer. Oncol Rev. 2012;6(1):e2–e2.
   PubMedGoogle Scholar
• Zendejas B, Moriarty JP, O’Byrne J, et al. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J clin oncol. 2011;29(22):2993.
   PubMed Web of Science ®Google Scholar
• Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev. 2009;18(3):718–725.
   PubMed Web of Science ®Google Scholar
• Jansen SJ, Stiggelbout AM, Wakker PP, et al. Patients’ utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med Decis Mak. 1998;18(4):391–399.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Jo M-W, Ock M, et al. Estimation of health state utilities in breast cancer. Patient Prefer Adherence. 2017;11:531.
   PubMed Web of Science ®Google Scholar
• Ashby J, O’hanlon M, Buxton MJ. The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? Qual Life Res. 1994;3(4):257–265.
   PubMed Web of Science ®Google Scholar
• Ram R, Singh J, McCaig E. Sentinel node biopsy alone versus completion axillary node dissection in node positive breast cancer: systematic review and meta-analysis. Int J Breast Cancer. 2014;2014:513780.
   PubMedGoogle Scholar
• de Gelder R, Bulliard JL, de Wolf C, et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer. 2009;45(1):127–138.
   PubMed Web of Science ®Google Scholar
• Zahoor S, Haji A, Battoo A, et al. Sentinel lymph node biopsy in breast cancer: a clinical review and update. J Breast Cancer. 2017;20(3):217–227.
   PubMed Web of Science ®Google Scholar
• Baron RH, Fey JV, Borgen PI, et al. Eighteen sensations after breast cancer surgery: a two-year comparison of sentinel lymph node biopsy and axillary lymph node dissection. Paper presented at: Oncology nursing forum2004. pubmed.ncbi.nlm.nih.gov/12011912/
   Google Scholar
• Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010;28(25):3929–3936.
   PubMed Web of Science ®Google Scholar
• Ara R, Wailoo A. NICE decision support unit technical support documents. In: NICE DSU technical support document 12: the use of health state utility values in decision models. London: National Institute for Health and Care Excellence (NICE); 2011. pubmed.ncbi.nlm.nih.gov/28481493/
   Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509–518.
   PubMed Web of Science ®Google Scholar
• Rafia R, Brennan A, Madan J, et al. Modeling the cost-effectiveness of alternative upper age limits for breast cancer screening in England and Wales. Value Health. 2016;19(4):404–412.
   PubMed Web of Science ®Google Scholar
• Roder D, Zorbas H, Kollias J, et al. Factors predictive of treatment by Australian breast surgeons of invasive female breast cancer by mastectomy rather than breast conserving surgery. Asian Pac J Cancer Prev. 2013;14(1):539–545.
   PubMedGoogle Scholar
• Roder D, Zorbas H, Kollias J, et al. Factors predictive of immediate breast reconstruction following mastectomy for invasive breast cancer in Australia. Breast. 2013;22(6):1220–1225.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GNCJ, D’Orsi CJ, Edge SB, et al. AJCC cancer staging manual. Vol. 11. Soman AD; Chicago, Illinois. 2010.
   Google Scholar
• StataCorp. Stata Statistical Software: release 15. College Station, TX: StataCorp LLC; 2017.
   Google Scholar
• Gannan E, Khoo J, Nightingale S, et al. Management of early node-positive breast cancer in Australia: a multicentre study. Breast J. 2016;22(4):413–419.
   PubMed Web of Science ®Google Scholar
• Pálka I, Kelemen G, Ormándi K, et al. Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res. 2008;14(2):161–167.
   PubMed Web of Science ®Google Scholar
• Sihto H, Lundin J, Lehtimäki T, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res. 2008;14(13):4103–4110.
   PubMed Web of Science ®Google Scholar
• Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Prev Biomarkers. 2005;14:1108–1112.
   PubMed Web of Science ®Google Scholar
• Lannin DR, Wang S. Are small breast cancers good because they are small or small because they are good? N Engl J Med. 2017;376(23):2286–2291.
   PubMed Web of Science ®Google Scholar
• Gu J, Groot G, Boden C, et al. Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early stage breast cancer: a systematic review. Clin Breast Cancer. 2018;18(4):e539-e554.
   PubMed Web of Science ®Google Scholar
• Anderson RT, Morris CR, Kimmick G, et al. Patterns of locoregional treatment for nonmetastatic breast cancer by patient and health system factors. Cancer. 2015;121(5):790–799.
   PubMed Web of Science ®Google Scholar
• Lei RY, Leonard CE, Nowels MA, et al. Patterns of surgical and radiation treatment for early-stage breast cancer in the state of Colorado. Int J Radiat Oncol Biol Phys. 2015;93(3,Supplement):E371.
   Web of Science ®Google Scholar
• Eunji H, Ling YM, M BM, et al. Variations in breast cancer histology and treatment patterns between the major ethnic groups of South West Sydney. Breast J. 2017.
   Web of Science ®Google Scholar
• King M, Kenny P, Shiell A, et al. Quality of life three months and one year after first treatment for early stage breast cancer: influence of treatment and patient characteristics. Qual Life Res. 2000;9(7):789–800.
   PubMed Web of Science ®Google Scholar
• Barratt AL, Irwig LM, Glasziou PP, et al. Benefits, harms and costs of screening mammography in women 70 years and over: a systematic review. Med J Aust. 2002;176(6):266–271.
   PubMed Web of Science ®Google Scholar
• Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):553–566.
   PubMed Web of Science ®Google Scholar
• Schleinitz MD, DePalo D, Blume J, et al. Can differences in breast cancer utilities explain disparities in breast cancer care? J Gen Intern Med. 2006;21(12):1253–1260.
   PubMed Web of Science ®Google Scholar
• Kornblith AB, Herndon JE 2nd, Weiss RB, et al. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98(4):679–689.
   PubMed Web of Science ®Google Scholar
• Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–493.
   PubMed Web of Science ®Google Scholar
• Koch L, Jansen L, Herrmann A, et al. Quality of life in long-term breast cancer survivors – a 10-year longitudinal population-based study. Acta Oncologica. 2013;52(6):1119–1128.
   PubMed Web of Science ®Google Scholar
• Gotay CC, Muraoka MY. Quality of life in long-term survivors of adult-onset cancers. J Natl Cancer Inst. 1998;90(9):656–667.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816.
   PubMed Web of Science ®Google Scholar